Science and technology
Glycostem harvests the power of allogeneic Natural Killer (NK) cells. NK cells arise from blood forming stem cells and are an important part of the body's innate immune system. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing" properties, caused by a shift of balance between activating and inhibitory cellular signals and antibody-dependent cellular cytotoxicity (ADCC). NK cells play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).
NK cells can be used as a stand-alone or add-on therapy allowing multiple treatment options. An allogeneic (partial mismatch) approach provides an excellent basis for effective treatment. In allogeneic stem cell transplantation (allo-SCT), NK cells have been shown to mediate graft-versus-leukemia (GVL) immunity towards recipient tumor cells without attacking recipients’ normal tissues, which would otherwise lead to graft-versus-host disease (GVHD).
Our in-house and GMP-compliant platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional, high-quality NK cells. This strategy allows us to generate highly pure, T cell devoid products without the use of any contaminating feeder cells. These cells are the basis of both our oNKord® and CAR-NK therapies. The technology platform is based on the use of closed bioreactor systems in combination with a proprietary synthetic, feeder cell-free, cell culture medium and a patented combination of growth factors. This enables off-the-shelf, safe and low production cost products.
Glycostem presented three posters demonstrating our novel NK cell therapeutics at the 19th Meeting of the Society for Natural Immunity (NK2022). Click on the links below to download these posters.
- Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cell-derived NK cell therapeutics: Clinical and preclinical evaluation of GTA002 and genetically modified candidates
- Multimodal activation of ex vivo expanded GTA002 NK cells efficiently targets melanoma
- Enabling treatment options against colorectal cancer by enhancing functionality of stem cell derived NK cells
Glycostem Poster at ASGCT 2020
More information about the development and manufacturing of the ‘off-the-shelf’ NK product oNKord®, and the next generation of novel treatment is available through the Glycostem poster presented at ASGCT 2020.
Click on the below link to play the audio to the poster. It is recommended to use Chrome, Firefox or Microsoft Edge to play the audio.
